tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

EXEL Stock Latest News

Exelixis price target raised to $53 from $47 at H.C. Wainwright
The FlyExelixis price target raised to $53 from $47 at H.C. Wainwright
3d ago
EXEL
Exelixis’s Promising STELLAR-303 Trial Results Lead to Buy Rating and Increased Approval Probability
PremiumRatings
Exelixis’s Promising STELLAR-303 Trial Results Lead to Buy Rating and Increased Approval Probability
3d ago
EXEL
NuScale, Hims & Hers, Snowflake, Advance Auto Parts, Exelixis: Trending by Analysts
PremiumWeekend Updates
NuScale, Hims & Hers, Snowflake, Advance Auto Parts, Exelixis: Trending by Analysts
5d ago
AAP
SMR
Exelixis price target raised to $50 from $42 at Jefferies
PremiumThe Fly
Exelixis price target raised to $50 from $42 at Jefferies
9d ago
EXEL
Lyft upgraded, Block assumed: Wall Street’s top analyst calls
PremiumThe Fly
Lyft upgraded, Block assumed: Wall Street’s top analyst calls
9d ago
EA
RH
Cautious Hold Rating for Exelixis Amid STELLAR-303 Trial Results and Regulatory Concerns
PremiumRatingsCautious Hold Rating for Exelixis Amid STELLAR-303 Trial Results and Regulatory Concerns
9d ago
EXEL
Exelixis upgraded to Overweight, named new ‘Best Idea’ at Stephens
Premium
The Fly
Exelixis upgraded to Overweight, named new ‘Best Idea’ at Stephens
9d ago
EXEL
Exelixis upgraded to Overweight from Equal Weight at Stephens
Premium
The Fly
Exelixis upgraded to Overweight from Equal Weight at Stephens
9d ago
EXEL
More data needed to determine Exelixis’ competitive positioning, says BofA
PremiumThe Fly
More data needed to determine Exelixis’ competitive positioning, says BofA
10d ago
EXEL
Exelixis price target raised to $55 from $43 at Truist
PremiumThe Fly
Exelixis price target raised to $55 from $43 at Truist
10d ago
EXEL
Exelixis price target raised to $50 from $47 at Citizens JMP
PremiumThe Fly
Exelixis price target raised to $50 from $47 at Citizens JMP
10d ago
EXEL
Exelixis: Promising Clinical Trial Success and Strong Future Prospects Drive Buy Rating
PremiumRatings
Exelixis: Promising Clinical Trial Success and Strong Future Prospects Drive Buy Rating
10d ago
EXEL
Exelixis announces ‘positive’ results from STELLAR-303 phase 3 trial
PremiumThe FlyExelixis announces ‘positive’ results from STELLAR-303 phase 3 trial
10d ago
EXEL
Exelixis says Ipsen receives positive CHMP opinion for Cabometyx
Premium
The Fly
Exelixis says Ipsen receives positive CHMP opinion for Cabometyx
13d ago
EXEL
Promising Clinical Data and Favorable Safety Profile Drive Buy Rating for Exelixis
Premium
Ratings
Promising Clinical Data and Favorable Safety Profile Drive Buy Rating for Exelixis
21d ago
EXEL
Exelixis price target raised to $47 from $40 at H.C. Wainwright
PremiumThe Fly
Exelixis price target raised to $47 from $40 at H.C. Wainwright
21d ago
EXEL
Exelixis price target raised to $46 from $45 at BofA
PremiumThe Fly
Exelixis price target raised to $46 from $45 at BofA
28d ago
EXEL
Exelixis’s Zanza Pipeline: Balancing Risks and Opportunities Ahead of Key 2025 Readouts
PremiumRatings
Exelixis’s Zanza Pipeline: Balancing Risks and Opportunities Ahead of Key 2025 Readouts
28d ago
EXEL
Exelixis Holds Annual Meeting, Elects New Directors
PremiumCompany Announcements
Exelixis Holds Annual Meeting, Elects New Directors
1M ago
8K
EXEL
Promising Clinical Data and Ongoing Trials Justify Buy Rating for Exelixis’s Zanzalintinib
PremiumRatingsPromising Clinical Data and Ongoing Trials Justify Buy Rating for Exelixis’s Zanzalintinib
1M ago
EXEL
Exelixis’s Growth Potential Highlighted by Promising STELLAR-002 Trial Results and Buy Rating
Premium
Ratings
Exelixis’s Growth Potential Highlighted by Promising STELLAR-002 Trial Results and Buy Rating
1M ago
EXEL
Promising Outlook for Exelixis: Buy Rating Backed by Zanzalintinib’s Efficacy and Anticipated Phase III Trial Success
Premium
Ratings
Promising Outlook for Exelixis: Buy Rating Backed by Zanzalintinib’s Efficacy and Anticipated Phase III Trial Success
1M ago
EXEL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
OSZAR »